-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The editor of WuXi AppTec's content team has been vaccinating the new crown vaccinations around the world, and the sporadic cases of new crown infections after vaccination have always been people's attention.
At the same time, the prevalence of mutant strains also poses potential challenges to the protective efficacy of vaccines.
Last weekend, the U.
S.
Centers for Disease Control and Prevention announced the data on vaccine breakthrough cases (individuals with new coronavirus RNA or antigen detected in respiratory samples ≥ 14 days after the completion of the new crown vaccination).
Among the more than 75 million people who completed the vaccination, the infection rate Less than one in ten thousand (about 0.
00775%).
Although these data generally support the effectiveness of the vaccine, paying attention to the cases of infections that have been "successful" after vaccination will help us better prevent and identify new crown infections.
Today, the "New England Journal of Medicine" published an important paper.
A research team from Rockefeller University reported the details of two vaccine breakthrough cases.
Laboratory tests and analysis showed that the two were indeed vaccinated.
There are a large number of neutralizing antibodies in the body, but the virus mutation may be the reason why the vaccine has not fully protected.
Screenshot source: The New England Journal of Medicine research team introduced that as of March 30, 2021, infections caused by the new crown mutant accounted for more than 72% of new cases in New York, including the B.
1.
1.
7 mutation originally discovered in the United Kingdom.
Strain (accounting for 26.
2% of cases) and the B.
1.
526 mutant strain originally found in New York (accounting for 42.
9% of cases).
The two major concerns about mutant strains are that the immune escape from the vaccine may cause asymptomatic infection (thus promoting the spread of the virus) or cause disease.
This research is based on long-term monitoring and tracking of all employees and students on the Rockefeller University campus.
Among 417 people who received the second dose of the new crown vaccine (Pfizer/BNT162b2 or Moderna mRNA-1273) for at least 2 weeks, the research team found 2 cases of vaccine breakthrough infection.
Patient's medical history Patient 1 is a healthy 51-year-old female.
She received two doses of mRNA-1273 vaccine on January 21 and February 19, 2021, while strictly following routine preventive measures.
On March 10 (19 days after the second dose of the vaccine), she developed symptoms such as sore throat, nasal congestion and headache, and subsequently tested positive for the new crown that day.
On March 11, the patient lost his sense of smell.
Within 1 week thereafter, the symptoms gradually subsided.
Patient 2 is a 65-year-old healthy woman.
She received two doses of Pfizer/BNT162b2 vaccine on January 19 and February 9, 2021.
On March 3, her partner (not vaccinated) tested positive for the new crown.
On March 16, she also began to experience fatigue, nasal congestion and headaches.
On March 17, her symptoms worsened and she tested positive for the new crown.
At this time, 36 days have passed since she completed the vaccination.
After March 20, her symptoms gradually eased.
Image source: WuXi AppTec's content team mapped the mutations of the infected virus.
The research team pointed out that the two patients received continuous nucleic acid testing before and during the onset.
When the infection was confirmed, the viral loads of the saliva nucleic acid test results of the two patients were 195,000 copies/ml and 400 copies/ml, respectively.
Considering that both patients have been vaccinated, the research team performed genetic sequencing on the S protein of the viral RNA used for nucleic acid detection in the samples.
The results showed that the genetic sequences of the new coronaviruses infected by the two patients were identical to those of the virus in the early stages of the epidemic.
There are many differences in the sequence, including some mutations that have attracted attention.
In patient 1, mutations included E484K (suspected to allow the new coronavirus to evade recognition by certain neutralizing antibodies) and D614G (increasing the spread of the new coronavirus).
In patient 2, these mutations included D614G and S477N.
Whole-genome sequencing of the excess RNA in patient 1’s saliva further confirmed these mutations in the S gene and suggested that the infection was caused by a mutant strain that was related to but not related to B.
1.
1.
7 and B.
1.
526.
Are not the same.
▲Test results of clinically influential mutations in the S gene of the new coronavirus in patients 1 and 2 (picture source: reference [1]) The antibody protection effect brought by the vaccine Next, in order to analyze whether the vaccine is working, the research team Serum samples of patient 1 were collected 4 days after the onset of illness.
The results of the pseudovirus neutralization experiment suggest that the neutralizing antibody titer in patient 1 is extremely high.
This suggests that the neutralizing antibodies in this patient may have been triggered by vaccination.
▲The serum neutralizing antibody titers of other recovered patients at 1.
3 months and 6.
2 months after infection (left), as well as the serum neutralizing antibody titers of the two-dose vaccine population and patient 1 after infection.
There was no significant difference in neutralizing antibody titers between the recovered patients and the vaccinated patients 1.
3 months after infection.
(Image source: Reference [1]) The research team continued to use patient 1's serum samples to test its effectiveness against wild-type new coronavirus, E484K mutation and B.
1.
526 mutant strains, and found that the serum has the same effect on each virus.
This means that the antibody response in patient 1 recognized these mutations, but it was still not enough to prevent breakthrough infections.
The case enlightenment research team pointed out that the two cases of mutated virus infection after vaccination highlight the need to continuously monitor a variety of new coronavirus mutations.
Related measures include virus detection in symptomatic and asymptomatic people, sequencing of viral RNA, and Monitor the titer of neutralizing antibodies. Read about the new crown research, how many people have been infected and died after taking the new crown vaccine? The real data of 75 million vaccinators across the United States released NEJM: For the new coronavirus mutant, Sinopharm and Kexing inactivated vaccine neutralization efficacy results were published.
For the new crown key mutant strain, Sinopharm and Zhifei vaccine neutralization efficacy data were published "The Lancet-Microorganism" 3 NEJM articles on the same day: The infection after vaccination is a case.
The new crown vaccine is generally effective in reducing 92% of new crown infections and 94% of cases among medical staff.
NEJM published data reference materials for 600,000 people vaccinated against Pfizer/BioNTech in Israel.
.
, (2021).
Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
The N Engl J Med, DOI: 10.
1056/NEJMoa2105000 Note: This article aims to introduce medical and health research progress, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
At the same time, the prevalence of mutant strains also poses potential challenges to the protective efficacy of vaccines.
Last weekend, the U.
S.
Centers for Disease Control and Prevention announced the data on vaccine breakthrough cases (individuals with new coronavirus RNA or antigen detected in respiratory samples ≥ 14 days after the completion of the new crown vaccination).
Among the more than 75 million people who completed the vaccination, the infection rate Less than one in ten thousand (about 0.
00775%).
Although these data generally support the effectiveness of the vaccine, paying attention to the cases of infections that have been "successful" after vaccination will help us better prevent and identify new crown infections.
Today, the "New England Journal of Medicine" published an important paper.
A research team from Rockefeller University reported the details of two vaccine breakthrough cases.
Laboratory tests and analysis showed that the two were indeed vaccinated.
There are a large number of neutralizing antibodies in the body, but the virus mutation may be the reason why the vaccine has not fully protected.
Screenshot source: The New England Journal of Medicine research team introduced that as of March 30, 2021, infections caused by the new crown mutant accounted for more than 72% of new cases in New York, including the B.
1.
1.
7 mutation originally discovered in the United Kingdom.
Strain (accounting for 26.
2% of cases) and the B.
1.
526 mutant strain originally found in New York (accounting for 42.
9% of cases).
The two major concerns about mutant strains are that the immune escape from the vaccine may cause asymptomatic infection (thus promoting the spread of the virus) or cause disease.
This research is based on long-term monitoring and tracking of all employees and students on the Rockefeller University campus.
Among 417 people who received the second dose of the new crown vaccine (Pfizer/BNT162b2 or Moderna mRNA-1273) for at least 2 weeks, the research team found 2 cases of vaccine breakthrough infection.
Patient's medical history Patient 1 is a healthy 51-year-old female.
She received two doses of mRNA-1273 vaccine on January 21 and February 19, 2021, while strictly following routine preventive measures.
On March 10 (19 days after the second dose of the vaccine), she developed symptoms such as sore throat, nasal congestion and headache, and subsequently tested positive for the new crown that day.
On March 11, the patient lost his sense of smell.
Within 1 week thereafter, the symptoms gradually subsided.
Patient 2 is a 65-year-old healthy woman.
She received two doses of Pfizer/BNT162b2 vaccine on January 19 and February 9, 2021.
On March 3, her partner (not vaccinated) tested positive for the new crown.
On March 16, she also began to experience fatigue, nasal congestion and headaches.
On March 17, her symptoms worsened and she tested positive for the new crown.
At this time, 36 days have passed since she completed the vaccination.
After March 20, her symptoms gradually eased.
Image source: WuXi AppTec's content team mapped the mutations of the infected virus.
The research team pointed out that the two patients received continuous nucleic acid testing before and during the onset.
When the infection was confirmed, the viral loads of the saliva nucleic acid test results of the two patients were 195,000 copies/ml and 400 copies/ml, respectively.
Considering that both patients have been vaccinated, the research team performed genetic sequencing on the S protein of the viral RNA used for nucleic acid detection in the samples.
The results showed that the genetic sequences of the new coronaviruses infected by the two patients were identical to those of the virus in the early stages of the epidemic.
There are many differences in the sequence, including some mutations that have attracted attention.
In patient 1, mutations included E484K (suspected to allow the new coronavirus to evade recognition by certain neutralizing antibodies) and D614G (increasing the spread of the new coronavirus).
In patient 2, these mutations included D614G and S477N.
Whole-genome sequencing of the excess RNA in patient 1’s saliva further confirmed these mutations in the S gene and suggested that the infection was caused by a mutant strain that was related to but not related to B.
1.
1.
7 and B.
1.
526.
Are not the same.
▲Test results of clinically influential mutations in the S gene of the new coronavirus in patients 1 and 2 (picture source: reference [1]) The antibody protection effect brought by the vaccine Next, in order to analyze whether the vaccine is working, the research team Serum samples of patient 1 were collected 4 days after the onset of illness.
The results of the pseudovirus neutralization experiment suggest that the neutralizing antibody titer in patient 1 is extremely high.
This suggests that the neutralizing antibodies in this patient may have been triggered by vaccination.
▲The serum neutralizing antibody titers of other recovered patients at 1.
3 months and 6.
2 months after infection (left), as well as the serum neutralizing antibody titers of the two-dose vaccine population and patient 1 after infection.
There was no significant difference in neutralizing antibody titers between the recovered patients and the vaccinated patients 1.
3 months after infection.
(Image source: Reference [1]) The research team continued to use patient 1's serum samples to test its effectiveness against wild-type new coronavirus, E484K mutation and B.
1.
526 mutant strains, and found that the serum has the same effect on each virus.
This means that the antibody response in patient 1 recognized these mutations, but it was still not enough to prevent breakthrough infections.
The case enlightenment research team pointed out that the two cases of mutated virus infection after vaccination highlight the need to continuously monitor a variety of new coronavirus mutations.
Related measures include virus detection in symptomatic and asymptomatic people, sequencing of viral RNA, and Monitor the titer of neutralizing antibodies. Read about the new crown research, how many people have been infected and died after taking the new crown vaccine? The real data of 75 million vaccinators across the United States released NEJM: For the new coronavirus mutant, Sinopharm and Kexing inactivated vaccine neutralization efficacy results were published.
For the new crown key mutant strain, Sinopharm and Zhifei vaccine neutralization efficacy data were published "The Lancet-Microorganism" 3 NEJM articles on the same day: The infection after vaccination is a case.
The new crown vaccine is generally effective in reducing 92% of new crown infections and 94% of cases among medical staff.
NEJM published data reference materials for 600,000 people vaccinated against Pfizer/BioNTech in Israel.
.
, (2021).
Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
The N Engl J Med, DOI: 10.
1056/NEJMoa2105000 Note: This article aims to introduce medical and health research progress, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
